Discover how targeted radiotherapy induced toxicity can be identified with imaging
Beyond RECIST: A comprehensive assessment of treatment response and toxicity in oncology studies
This Pharma IQ webinar with AIQ explores how AI-assisted analysis of radiological scans enhances the understanding of treatment efficacy
We respect your privacy, by clicking ‘Watch On Demand’ you agree to receive our e-newsletter, including information on Podcasts, Webinars, event discounts and online learning opportunities. For further information on how we process and monitor your personal data click here. You can unsubscribe at anytime.
Watch On-Demand
The current standards of quantifying the treatment response for oncology studies such as RECIST and blood tests neglect the impact of intra-patient heterogeneity.
Artificial intelligence (AI) technologies continue to gain traction, by delivering in-depth assessments of treatment response and their relationship to adverse event burdens. Weill Cornell Medicine applied AIQ Solutions’ technology to patients with prostate cancer who had been treated with prostate-specific membrane antigen (PSMA)-targeted radiotherapy (known as 177Lu-PSMA-617).
Join this webinar to learn how AI-assisted analysis of radiological scans enhances the understanding of treatment efficacy and adverse effects.
Join this webinar to find out:
- What the landscape of PSMA-based radiotherapy is like
- How using imaging analytics can support the earlier prediction of adverse events
- How automated image analysis can improve treatment response assessment
Speakers
Nauseef specializes in genitourinary (GU) cancers and Phase I clinical trials, including using PSMA-targeted radionuclide therapies. His research is focused on genomics of advanced prostate cancers, including neuroendocrine prostate cancer and healthcare disparities.
Perk provides strategic leadership, directs a team of research scientists, manages external research collaborations and designs and implements scalable technical solutions for AIQ's innovative products. These include the development of new algorithms, making improvements to process automation, and enhancing the accuracy and performance of software components. He is also an inventor of AIQ’s intellectual property.
Sponsor
We respect your privacy, by clicking ‘Watch On Demand’ you agree to receive our e-newsletter, including information on Podcasts, Webinars, event discounts and online learning opportunities. For further information on how we process and monitor your personal data click here. You can unsubscribe at anytime.
Watch On-Demand